

May 20, 2025

Listing Department **BSE LIMITED** P J Towers, Dalal Street, <u>Mumbai–400 001</u> Code: 532321

Listing Department **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Code: ZYDUSLIFE

Re: Outcome of Board Meeting

Ref.: <u>Disclosures under SEBI (Listing Obligations and Disclosure Requirements)</u> <u>Regulations, 2015 ("the Listing Regulations")</u>

Dear Sir / Madam,

The Board of Directors ("the **Board**") at their meeting held today i.e. May 20, 2025, based on the recommendations of Audit Committee, approved the audited financial results for the quarter / year ended on March 31, 2025.

In this regard, please find enclosed the following:

- 1. the audited financial results (standalone and consolidated) for the quarter / year ended on March 31, 2025, reviewed by the Audit Committee and taken on record by the Board pursuant to regulation 33 of the Listing Regulations.
- the audit reports of Deloitte Haskins & Sells LLP, Chartered Accountants and the Statutory Auditors of the Company ("Deloitte") certifying the audit of the financial results (standalone and consolidated) of the Company for the quarter / year ended on March 31, 2025, pursuant to regulation 33 of the Listing Regulations.

Pursuant to the SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016, we hereby declare that Deloitte have submitted their audit reports (both, standalone and consolidated) on the audited financial statements for the year ended on March 31, 2025, with an unmodified opinion.



Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000 website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



The Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed for trading till Thursday, May 22, 2025, and shall reopen on and from Friday, May 23, 2025, for the Directors and Designated Persons.

The Board also recommended final dividend of Rs. 11/- (@1100%) per equity share of Re. 1/- each, subject to approval of the shareholders at the ensuing Annual General Meeting scheduled to be held on August 12, 2025.

The financial results and audit reports will be available on the website of the Company at <u>www.zyduslife.com</u>.

The Board meeting commenced at 12:00 noon and concluded at 1:00 p.m.

Please receive the information and disclosures in order.

Thanking you,

Yours faithfully, For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI COMPANY SECRETARY AND COMPLIANCE OFFICER MEMBERSHIP NO. FCS7063

Encl.: As above



Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000 website : www.zyduslife.com | CIN : L24230GJ1995PLC025878

Chartered Accountants 19th Floor, Shapath-V S.G. Highway Ahmedabad - 380 015 Gujarat, India

Tel: +91 79 6682 7300 Fax: +91 79 6682 7400

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ZYDUS LIFESCIENCES LIMITED

Opinion and Conclusion

We have (a) audited the Standalone Financial Results for the year ended March 31, 2025 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2025 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the Quarter and Year Ended March 31, 2025 of **Zydus Lifesciences Limited** (the "Company"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

(a) Opinion on Annual Standalone Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2025:

- are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2025

With respect to the Standalone Financial Results for the quarter ended March 31, 2025, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2025, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2025

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued



ce: One International Center, Tower 3, 31st floor, Senapati Bapat Marg, Elphinstone Road (West), Mumbai-400 013, Maharashtra, India. Haskins & Sells LLP is registered with Limited Liability having LLP identification No: AAB-8737 by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2025 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's and Board of Directors' Responsibilities for the Statement

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2025 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the guarter and year ended March 31, 2025 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors is responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities

(a) Audit of the Standalone Financial Results for the year ended March 31, 2025

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2025 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Page 3 of 4

(b) Review of the Standalone Financial Results for the quarter ended March 31, 2025

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2025 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Other Matters

• The Statement includes the results for the Quarter ended March 31, 2025 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.

Our report on the Statement is not modified in respect of this matter.

For Deloitte Haskins & Sells LLP Chartered Accountants (Firm's Registration No. 117366W/W-100018)



Kostikeya Kaval

Kartikeya Raval Partner Membership No. 106189 UDIN: 25106189BMNRJK9143

Place: Ahmedabad Date: May 20, 2025

		LC025878				
	Statement of Standalone Financial Results for the C	Quarter and Year Ended Ma		Rupees in Million		_
		3 Months ended 31/03/2025	Preceding 3 Months ended 31/12/2024	Corresponding 3 Months ended 31/03/2024 in the previous year	Year ended 31/03/2025	Previ e 31/0
C N		(Unaudited)	(Lineudited)	(Unaudited)	(audited)	
Sr. No. 1	Particulars Income	(Refer Note-8)	(Unaudited)	(Refer Note-8)	(Audited)	(A)
	Revenue from operations					
	Sale of products	56,335	24,089	31,726	145,901	
n	Other operating revenues	1,861	1,070	1,598	5,262	1.1
ш	Total revenue from operations	58,196	25,159	33,324	151,163	1
1	Other income (Refer Note-4)	1,854	775	3,611	6,962	-
	Total income	60,050	25,934	36,935	158,125	
	Expenses				2.45	
	Cost of materials consumed	7,208	6,358	7,372	27,871	
	Purchases of stock-in-trade	930	1,121	711	3,509	
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,236)		(862)	(1,211)	
	Employee benefits expense Finance costs	4,763	4,250	4,051	17,622	
		1,554	972	1,062 1,306	4,639	
	Depreciation and amortisation expense Other expenses	1,280 8,296	1,316 7,178	6,437	5,239 28,105	
-	Net loss/ (gain) on foreign currency transactions	508	(2,111)	(77)	(2,096)	
	Total expenses	23,303	20,962	20,000	83,678	
	Profit before exceptional items and tax (1-2)	36,747	4,972	16,935	74,447	
	Exceptional item (Refer Note-5)	-	-	86	-	
	Profit before tax (3-4)	36,747	4,972	16,849	74,447	
6	Tax expenses (Refer Note-6)					1
а	Current tax	8,265	(242)	4,075	15,825	
b	Deferred tax	345	508	(1,278)	873	-
	Total tax expenses	8,610	266	2,797	16,698	
7	Net Profit for the period/ year (5-6)	28,137	4,706	14,052	57,749	1 - 3
8	Other Comprehensive Income (OCI)					
1000	Items that will not be reclassified to profit or loss:					
	Re-measurement (losses)/ gains on post employment defined benefit plans	5	(87)	(82)	(258)	
	Net gain/ (loss) on Fair Value through OCI Equity Securities	103	48	(108)	270	
	Income tax effect on above items	4	7	20	52	
iv	Other Comprehensive Income (net of tax)	112	(32)	(170)	64	
9	Total Comprehensive Income (7+8)	28,249	4,674	13,882	57,813	
	Paid-up equity share capital (Face value Re. 1/-)	1,006	1,006	1,006	1,006	-
	Reserves excluding Revaluation Reserve (i.e. Other Equity)				210,895	1
1.2	Earnings per share (not annualised for the quarter)					
а	Basic (Rs.)	27.96	4.68	13.89	57.39	
b	Diluted (Rs.)	27.96	4.68	13.89	57.39	1.1
Notes :						-
 [2] The Con [3] The [4] Othe [5] Exce own [6] For Act, 31, sect the und its t qua [7] In a 	above financial results were reviewed by the Audit Committee and then approved by the Board of se financial results have been prepared in accordance with the Companies [Indian Accounting States apanies Act, 2013, read with relevant rules issued thereunder. Board of Directors has recommended a dividend of INR 11/- [@ 1,100%] per equity share on 1,0 recommended dividend is subject to the approval of the shareholders at the ensuing Annual Gener income includes dividend from subsidiaries and joint ventures, of INR 821 Million for the quarter vious year, the same was INR 1,531 Million for the quarter and INR 6,013 Million for the year end aptional item for the quarter and year ended March 31, 2024 of INR 86 Millions comprises loss on ted subsidiary, on closure of business operations of ZNI. the financial year ended March 31, 2024, the Company had computed the provision for income ta 1961 would be exercised while filing the income tax return for the said financial year. Accordingl 2024 and re-measured its deferred tax assets and liabilities basis the rate prescribed in the said sion 115BAA of the Income Tax Act, 1961 was required to be taken by the Company at the time of quarter ended December 31, 2024, while filing the income tax return for the financial year ender ax provisions, the full impact of which has been recognised in the statement of Profit and Loss for rter ended December 31, 2024 and quarter and year ended March 31, 2025 are not comparable. iccordance with Ind AS 105 "Non-Current Assets held for Sale and Discontinued Operations", inve- n Investments and disclosed separately at the lower of its carrying value and fair value less costs	andards] Rules, 2015 [Ind AS] 206,233,990 equity shares of I teral Meeting. er ended March 31, 2025 and ed March 31, 2024. I disposal of investment made ax assuming that the option pro- y, the Company had recognise tection. The final decision with of filing the income tax return d March 31, 2024, the Compan- provisions of the Income Tax r the quarter ended December estment in Bayer Zydus Pharm	as amended, pr NR 1/- each for INR 3,004 for th in common stoc ermitted under s ed provision for i respect to the e for the year end ny has decided r Act, 1961. Acco r 31, 2024. Hend	escribed under S the financial year e year ended Ma k of Zydus Novel section 115BAA of ncome tax for the election of the sai ed March 31, 202 not to exercise the rdingly, the Comp se, the tax expen	r ended on Man rch 31, 2025. D tech Inc. [ZNI], f the Income Ta e year ended M d option under 24. However, du e option permitt pany has re-me ses for the	ch 31, ; ouring the a whole ax arch uring ted asured

Audited Standalone Statement of Assets and		. Come
	Rupees in As at	n Million As at
Particulars	31/03/2025	31/03/2024
ASSETS		
1 Non-current assets		
a Property, plant and equipment	41,358	43,257
b Capital work-in-progress	11,885	6,267
c Other intangible assets	663	437
d Intangible assets under Development		72
e Financial assets		
i Investments	72,550	72,830
ii Loans	41,190	36,406
iii Other Financial Assets	152	144
f Other non-current assets	1,457	1,408
g Assets for Current tax (Net)	767	669
Sub-total - Non-current assets	170,022	161,490
2 Current assets		101/100
a Inventories	19,521	16,873
b Financial assets	10,521	10,075
i Investments	42,365	
ii Trade receivables	81,618	47,401
iii Cash and cash equivalents	1,030	1,081
iv Bank balance other than cash and cash equivalents	411	3,063
v Loans	1,251	1,048
vi Other current financial assets	4,147	1
c Other current assets		5,973
Sub-total - Current assets	2,804	3,674
	153,147	79,113
Assets classified as held for sale (Refer Note-7)	222.452	245
TOTAL - ASSETS	323,169	240,848
EQUITY AND LIABILITIES		
1 Equity	1.005	1.000
a Equity share capital	1,006	1,006
b Other equity	210,895	156,159
Sub-total - Equity	211,901	157,165
2 Non-current liabilities		
a Financial liabilities		
i Borrowings	28,621	55,554
ii Lease liabilities	21	35
iii Other financial liabilities	287	246
b Provisions	2,369	1,851
c Deferred tax liabilities (Net)	1,456	583
Sub-total - Non-current liabilities	32,754	58,269
3 Current liabilities		
a Financial liabilities		
i Borrowings	54,766	6,181
ii Lease liabilities	14	13
iii Trade payables		1
- Due to Micro and Small Enterprises	321	161
- Due to other than Micro and Small Enterprises	11,995	10,957
iv Other financial liabilities	5,288	4,420
b Other current liabilities	1,087	1,154
c Provisions	1,179	1,054
d Current tax liabilities (Net)	3,864	1,474
Sub-total - Current liabilities	78,514	25,414
TOTAL - EQUITY AND LIABILITES	323,169	240,848



. .

	Rupees in	n Million	
	Year e		
Particulars	31/03/2025	31/03/2024	
Cash flows from operating activities:	10		
Profit before tax	74,447	42,398	
Adjustments for: Depreciation and Amortisation expense	5,239	5,044	
Exceptional Items [Refer Note-5]	5,235	86	
[Gain] on disposal of Property, Plant and Equipment [Net]	(349)	(136)	
FVTPL gain/ profit on sale of investments [Net]	(282)	(142)	
Interest income	(3,227)	(3,221)	
Loss/ [Gain] on valuation of Forward Contract value related to investment in a Joint Venture	60	(976)	
Dividend income	(3,012)	(6,023)	
Interest expenses	4,613	3,882	
Net Loss on Fair Valuation of Swap Contract	191		
Effect of foreign exchange movement	(757)	(496)	
Trade receivables written off	5 233	-	
Expected credit loss on trade receivables [Net] Doubtful advances written off	233 144	184	
Allowance for doubtful advances [Net of written back]	8	22	
Provision for employee benefits	248	216	
Provision for probable product expiry claims and return of goods [Net of written back]	137	70	
Total	3,251	(1,490)	
Operating profit before working capital changes	77,698	40,908	
Adjustments for:			
[Increase] in trade receivables	(34,648)	(12,632)	
[Increase]/ Decrease in inventories	(2,648)	951	
Decrease/ [Increase] in other assets	2,624	(1,044)	
Increase in trade payables Increase/ [Decrease] in other liabilities	1,121 474	910 (113)	
Total	(33,077)	(11,928)	
Cash generated from operations	44,621	28,980	
Income taxes paid [Net of refunds]	(13,481)	(8,977)	
Net cash from operating activities	31,140	20,003	
Cash flows from investing activities:		4	
Purchase of property, plant and equipment and intangible assets [including payment towards			
capital work-in-progress, intangible asset under development and capital advances]	(9,049)	(5,854)	
Proceeds from sale of property, plant and equipment and intangible assets	478	188	
Purchase of non current investments in subsidiaries	(3,254)	(26,707)	
Proceeds from redemption of non current investments in a subsidiary/ joint venture	3,785	182	
Proceeds from redemption of non current investments in others Change in Bank balances (including fixed deposits) not considered as cash and cash equivalents	200 2,652	(487)	
[Investments in]/ redemption of current investments [Net]	(42,075)	2,158	
Loans to subsidiaries	(10,782)	(828)	
Repayment of loans by subsidiaries	6,367	4,056	
Interest received	3,630	2,951	
Dividend received	3,012	6,023	
Net cash [used in] investing activities	(45,036)	(18,318)	
Cash flows from financing activities:	Turker		
Proceeds from non current borrowings	10,566	20,625	
Repayment of non current borrowings Buyback of equity shares [including tax and transaction costs]	(12,928)	(3,608) (7,250)	
Current borrowings [Net - Proceeds/ (repayment)]	24,025	· (3,523)	
Lease liabilities [Net]	(17)	14	4
Interest paid	(4,777)	(3,191)	
Dividends paid	(3,024)	(6,075)	
Net cash [used in] financing activities	13,845	(3,008)	
Net [decrease] in cash and cash equivalents	(51)	(1,323)	
Cash and cash equivalents at the beginning of the year	1,081	2,404	
Cash and cash equivalents at the end of the year	1,030	1,081	
litional Information:			
nmary of Cash and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 n	nonths:		
ticulars	31/03/2025	31/03/2024	۹.
Cash and cash equivalents	1,030	1,081	
Bank balance other than cash and cash equivalents	411	3,063	
Current Investments	42,365	-	
Fixed Deposits more than 12 month's maturity	1	1	
Total	43,807	4,145 ,	
bad, May 20, 2025			By Arder of the Board For Zydus lifesciences Limiter Di Sharvil P. Pat Managing Directo
Station Purpos			DIN: 0013199
CONTRACTOR OF CONTRACTOR			

MUMBAI

ation Purp

LLP .

Chartered Accountants 19th Floor, Shapath-V S.G. Highway Ahmedabad - 380 015 Gujarat, India

Tel: +91 79 6682 7300 Fax: +91 79 6682 7400

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ZYDUS LIFESCIENCES LIMITED

Opinion and Conclusion

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2025 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2025 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Consolidated Financial Results for the Quarter and Year Ended March 31, 2025" of **Zydus Lifesciences Limited** (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as the "Group"), and its share of the net profit/(loss) after tax and other comprehensive loss of its joint ventures for the quarter and year ended March 31, 2025, (the "Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

(a) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on separate financial statements of subsidiaries and joint ventures referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2025:

- (i) includes the financial results of the entities listed in the Annexure to this report.
- (ii) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group for the year ended March 31, 2025.

(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2025

With respect to the Consolidated Financial Results for the quarter ended March 31, 2025, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the audit / review reports of the other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2025, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)



Sofrice: One International Center, Tower 3, 31st floor, Senapati Bapat Marg, Elphinstone Road (West), Mumbai-400 013, Maharashtra, India. Itte Haskins & Sells LLP is registered with Limited Liability having LLP identification No: AAB-8737 Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2025

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Group and joint ventures in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2025 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.

Management's and Board of Directors' Responsibilities for the Statement

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2025, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2025 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group including its joint ventures in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations.

The respective Board of Directors of the companies included in the Group and of its joint ventures are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and its joint ventures and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group and of its joint ventures are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.



The respective Board of Directors of the companies included in the Group and of its joint ventures are responsible for overseeing the financial reporting process of the Group and of its joint ventures.

Auditor's Responsibilities

(a) Audit of the Consolidated Financial Results for the year ended March 31, 2025

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2025 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its joint ventures to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its joint ventures to cease to continue as a going concern.



- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the LODR Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the entities within the Group and its joint ventures to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Annual Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

We communicate with those charged with governance of the Parent and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2025

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2025 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Other Matters

- The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report is not modified in respect of this matter.
- We did not audit the financial statements of subsidiaries included in the consolidated financial results, whose financial statements reflect total assets of Rs. 3,41,853 million as at March 31, 2025 and total revenues of Rs. 48,026 million and Rs. 1,73,409 million for the quarter and year ended March 31, 2025 respectively, total net loss after tax of Rs. 1,207 million and Rs. 8,050 million for the guarter and year ended March 31, 2025 respectively and other comprehensive loss of Rs. 7 million and Rs. 6 million for the guarter and year ended March 31, 2025 respectively and net cash inflows of Rs. 2,691 million for the year ended March 31, 2025, as considered in the Statement. The consolidated financial results also includes the Group's share of total net profit after tax of Rs. Nil and Rs. 146 million for the quarter and year ended March 31, 2025 respectively and other comprehensive loss of Rs. Nil and Rs. 1 million for the quarter and year ended March 31, 2025 respectively, as considered in the Statement, in respect of a joint venture whose financial statements have not been audited by us. These financial statements have been audited/ reviewed, as applicable, by other auditors whose reports have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and a joint venture, is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above.

Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

The consolidated financial results includes the unaudited financial statements of subsidiaries, whose financial statements reflect total assets of Rs. 52,333 million as at March 31, 2025 and total revenues of Rs. 4,053 million and Rs. 12,873 million for the quarter and year ended March 31, 2025 respectively, total net profit / (loss) after tax of Rs. (707) million and Rs. 641 million for the quarter and year ended March 31, 2025 respectively and other comprehensive loss of Rs. 3 million and Rs. 1 million for the quarter and year ended March 31, 2025 respectively and net cash inflows of Rs. 1,178 million for the year ended March 31, 2025, as considered in the Statement. The consolidated financial results also includes the Group's share of profit/(loss) after tax of Rs. (51) million and Rs. 433 million for the guarter and year ended March 31, 2025 respectively and other comprehensive loss of Rs. 18 million and Rs. 17 million for the guarter and year ended March 31, 2025 respectively, as considered in the Statement, in respect of certain joint ventures, whose financial statements have not been audited by us. These financial statements are unaudited and have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and joint ventures, is based solely on such unaudited financial statements. In our opinion and



according to the information and explanations given to us by the Board of Directors, these financial statements are not material to the Group.

Our report on the Statement is not modified in respect of the above matter with respect to our reliance on the financial statements certified by the Board of the Directors.

For Deloitte Haskins & Sells LLP Chartered Accountants

(Firm's Registration No. 117366W/W-100018)



Kartikeya Kaval

Kartikeya Raval Partner Membership No. 106189 UDIN: 25106189BMNRJL9299

Place: Ahmedabad Date: May 20, 2025

ASKINS

AHMEDABAD

ANNEXURE TO THE INDEPENDENT AUDITOR'S REPORT:

The Parent 1. Zydus Lifesciences Limited List of Subsidiaries 1. Sentynl Therapeutics Inc. 2. Zydus Animal Health and Investments Limited 3. Zydus Healthcare (USA) LLC 4. Zydus Healthcare Limited 5. Zydus Healthcare Philippines Inc. 6. Zydus International Private Limited 7. Zydus (Lanka) Private Limited 8. Zydus Pharmaceuticals (USA) Inc. 9. Zydus Wellness Limited 10. Zydus Worldwide DMCC 11. Dialforhealth Greencross Limited 12. Dialforhealth Unity Limited 13. Zydus Pharmaceuticals Limited 14. Zydus Strategic Investments Limited 15. Zydus VTEC Limited 16. Zynext Ventures PTE. LTD. 17. Zydus Pharmaceuticals UK Limited 18. Zydus Pharmaceuticals Canada Inc. 19. Zydus Lifesciences Global FZE 20. Viona Pharmaceuticals Inc., USA 21. Violio Healthcare Limited 22. Biochem Pharmaceutical Private Limited 23. Zydus Medtech Private Limited (w.e.f. May 31, 2024) 24. German Remedies Pharmaceuticals Private Limited 25. M/s. Recon Pharmaceuticals and Investments 26. Zydus Pharmaceuticals Mexico SA De CV 27. Zydus Pharmaceuticals Mexico Services Company SA De C.V. 28. Nesher Pharmaceuticals (USA) Inc. (till October 25, 2024) 29. ZyVet Animal Health Inc [USA] 30. Liva Investment Limited (Under liquidation) 31. Liva Nutritions Limited 32. Zydus Wellness Products Limited 33. Zydus Wellness International DMCC 34. Zydus Wellness BD Private Limited 35. Naturell (India) Private Limited (w.e.f. December 02, 2024) 36. Naturell Inc. (USA) (w.e.f. December 02, 2024) 37. Alidac Healthcare Myanmar Limited 38. Etna Biotech S.R.L. 39. Zydus France SAS 40. Zydus Healthcare S.A. (Pty) Ltd. 41. Zydus Netherland B.V 42. Zydus Therapeutics Inc. 43. Script Management Services (Pty) Ltd. 44. Alidac Pharmaceuticals SA (Pty) Ltd.

- 45. Laboratorios Combix S.L.
- 46. Zydus Nikkho Farmaceutica Ltda.
- 47. Zynext Ventures USA LLC, USA
- 48. LiqMeds Worldwide Limited
- 49. LiqMeds Limited
- 50. Medsolutions (Europe) Limited
- 51. LiqMeds Lifecare Limited
- 52. LM Manufacturing Limited
- 53. LM Manufacturing India Private Limited

List of Joint Ventures

- 1. Bayer Zydus Pharma Private Limited (till May 06, 2024)
- 2. Zydus Hospira Oncology Private Limited
- 3. Zydus Takeda Healthcare Private Limited
- 4. Oncosol Limited
- 5. Sterling Biotech Limited (w.e.f. August 29, 2024)



licated	Registered Office: Zydus Corporate Park, Scheme No. 63, Survey Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Tel. No.: (+91-79) 4804 0000 Website: www.a	bds 62,002 51,235 51,64 125,738 139,212 up rownes 2,277 1.466 1.674 6.677 523 us from operations 65,279 52,691 55,338 22,415 195,477 nem 66,085 52,266 55,002 225,110 195,417 195,497 ential consumed 11,644 10,255 1,210 43,729 45,600 of stock-in-trade 6,399 6,721 5,726 3,729 42,600 18,977 interactivity of inhide goods, work-in-progress and stock-in-trade 6,399 4,742 (1,4172) (1,6197) 63,278 43,729 42,509 13,377 trade groups 2,799 2,230 2,635 5,158 7,641 store 394 (1,628) (1,42) (1,42) 12,627 14,62 trade store 2,199 1,220 1,641 15,720 1,72 7,84 trade store 11,621 11,841 15,700 6,2,67 48,503 <				
		d Year Ended Ma	arch 31, 2025			
		ended	Preceding 3 Months ended	Corresponding 3 Months ended 31/03/2024 in the previous		endec
	(1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.					No. Co
No.	Particulars Income	(Refer Note-11)	(Unaudited)	(Refer Note-11)	(Audited)	(Audite
	Revenue from operations	1.1.1.1				
i	Sale of products			and the second se		
	Other operating revenues					
	Other income					
	Total income				Contra Contra	
	Expenses					
	Cost of materials consumed	- At				
1000	Purchases of stock-in-trade	1				5.4
100	Changes in inventories of finished goods, work-in-progress and stock-in-trade Employee benefits expense					
	Finance costs			10 - P. W.		
	Depreciation and amortisation expense	2,379	2,290	2,053		7
g	Other expenses	16,945	15,342		63,278	48
1.22	Net loss/ (gain) on foreign currency transactions				1	
	Total expenses					
- 1	Exceptional items [Net] (Refer Note-5)		-	-		40
	Profit before tax and share of profit of joint ventures (3-4) Tax expenses (Refer Note-6)		11,841	15,470		4
а	Current tax					
	Deferred tax					
	Total tax expenses					
	Share of (loss)/ profit of joint ventures (net of tax)					
	Net profit before non-controlling interests (7+8)		10,265	12,429		
	Non-controlling interests	728	27	638	1,471	
	Net Profit for the period/ year from continuing operations (9-10)	11,709		1.	45,255	3
			(4)			
		1		(5)	-	
	Net profit for the period/ year (11+12)	11,709			45,255	3
	Other Comprehensive Income (OCI)					
	Items that will not be reclassified to profit or loss:					
i	Re-measurement (losses)/ gains on post employment defined benefit plans	(5)	(114)	(109)	(365)	
-	Net gain/ (loss) on Fair Value through OCI Equity Securities					
	Income tax effect on above items					-
	Total Items that will be reclassified to profit or loss	112	(58)	(302)	(5)	
100	Exchange differences on translation of foreign operations	(322)	(373)	(1,401)	(977)	(
	Income tax effect on above items		-	-	-	,
ш	Total	(322)	(373)	(1,401)	(977)	(
1.1	Share of OCI of joint-ventures (net of tax)		-	1		
	Other Comprehensive Income (net of tax) before Non-Controlling Interests		(431)	(1,705)	1911	(
	Non-Controlling Interests Other Comprehensive Income (net of tax)		(431)	(1.705)		1
	Total Comprehensive Income (9+12+14 d)			1	1.1.1	1 3
	Total Comprehensive Income attributable to:				1.0	
	Owners of the Company	11,483	9,804	10,118	44,257	3
	Non-Controlling Interests	726	27	638	1,469	
	Paid-up equity share capital (Face value Re. 1/-)	1,006	1,006	1,006	1,006	1.17
	Reserves excluding Revaluation Reserve (i.e. Other Equity)				238,525	19
	Earnings per share for continuing operations (not annualised for the quarter) Basic (Rs.)	11.64	10.18	11.66	44.97	
		11.64	10.18	11.66	44.97	
A	FarBings per share for discontinued operations (not annualised for the quarter)			and and		
HAS	THE TRONG		(0.01)		-	
1	Dilotted (Rei)		(0.01)	0.03	· •	
C	Diluted (Rs.) Earnings per share for discontinued operations (not annualised for the quarter) Earnings per share for continuing & discontinued operations (not annualised for the quarter) Earnings per share for continuing & discontinued operations (not annualised for the quarter) Earnings per share for continuing & discontinued operations (not annualised for the quarter) Earnings per share for continuing & discontinued operations (not annualised for the quarter) Earnings per share for continuing & discontinued operations (not annualised for the quarter) Earnings per share for continuing & discontinued operations (not annualised for the quarter)	11.64	10.17	11.69	44.97	0.1
MIN		11.04	10.1/	11.05	17.3/	

		-	F	Rupees in Million		
		3 Months ended 31/03/2025	Preceding 3 Months ended 31/12/2024	Corresponding 3 Months ended 31/03/2024 in the previous year	Year ended 31/03/2025	Previous yea ended 31/03/2024
Sr. No.	Particulars	(Unaudited) (Refer Note-11)	(Unaudited)	(Unaudited) (Refer Note-11)	Pre Ye-ar ended 31/03/2025 31 (Audited) (/ 205,439 26,976 232,415 58,993 3,470 62,463 307,628 64,389 372,017 101,090 7,343	(Audited)
1	Segment revenue:					
a	Pharmaceuticals	56,172	48,099	47,542	205,439	172,354
b	Consumer Products	9,107	4,592	7,796	26,976	23,120
c	Total revenue from operations from continuing operations	65,279	52,691	55,338	232,415	195,474
2	Segment results:		1.000	1.		
a	Pharmaceuticals	17,196	11,753	14,006	58,993	45,568
b	Consumer Products	1,720	88	1,464	3,470	2,663
c	Total profit before tax before exceptional items from continuing operations	18,916	11,841	15,470	62,463	48,231
3	Segment assets [*]:			C. D.		
a	Pharmaceuticals	307,628	267,994	231,348	307,628	231,348
b	Consumer Products	64,389	61,362	61,460	64,389	61,460
c	Total assets	372,017	329,356	292,808	372,017	292,808
4	Segment liabilities:		1			
а	Pharmaceuticals [*]	101,090	72,293	65,745	101,090	65,745
b	Consumer Products	7,343	5,682	6,047	7,343	6,047
c	Total liabilities	108,433	77,975	71,792	108,433	71,792
	[*] includes amounts in respect of discontinued operations and assets held for sale (Refer Note-7)					

[2] The above financial results were reviewed by the Audit Committee and then approved by the Board of Directors at their meetings held on May 20, 2025.

[3] These financial results have been prepared in accordance with the Companies [Indian Accounting Standards] Rules, 2015 [Ind AS] as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.

[4] The Board of Directors of the Parent has recommended a dividend of INR 11/- [@ 1,100%] per equity share on 1,006,233,990 equity shares of INR 1/- each for the financial year ended on March 31, 2025. The recommended dividend is subject to the approval of the shareholders at the ensuing Annual General Meeting.

[5] Exceptional items comprise:

E HASKINS &

MUMBAI

ation Pur

	Rupees in Million					
	3 Months ended 31/03/2025	Preceding 3 Months ended 31/12/2024	Corresponding 3 Months ended 31/03/2024 in the previous year	Year ended 31/03/2025	Previous year ended 31/03/2024	
lo. Particulars	(Unaudited) (Refer Note-11)	(Unaudited)	(Unaudited) (Refer Note-11)	(Audited)	(Audited)	
Expenses incurred in connection with cessation of the operations of one of the manufacturing facilities of Zydus Wellness Products Limited [ZWPL], a subsidiary of the Group		-	-		177	
b Gain on sale of assets by ZWPL which were classified as "Assets held for sale" from Property, Plant and Equipment in the financial year 2022-23 [as per Ind AS 105]	-	•	-	4	(35)	
c Impairment of Goodwill related to Brazil business	1,350	-		1,350	-	
d Impairment of a product related intangible held by Zydus Worldwide DMCC, a wholly owned subsidiary	846	-		846		
e Total	2,196	-	-	2,196	142	

[6] a For the financial year ended March 31, 2024, the Parent had computed the provision for income tax assuming that the option permitted under section 115BAA of the Income Tax Act, 1961 would be exercised while filing the income tax return for the said financial year. Accordingly, the Parent had recognised provision for income tax for the year ended March 31, 2024 and re-measured its deferred tax assets and liabilities basis the rate prescribed in the said section. The final decision with respect to the election of the said option under section 115BAA of the Income Tax Act, 1961 was required to be taken by the Parent at the time of filing the income tax return for the year ended March 31, 2024. However, during the quarter ended December 31, 2024, while filing the income tax return for the financial year ended March 31, 2024, the Parent has decided not to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 and rather has filed the return as per the normal provisions of the Income Tax Act, 1961. Accordingly, the Parent has re-measured its tax provisions, the full impact of which has been recognised in the statement of Profit and Loss for the quarter ended December 31, 2024 and year ended March 31, 2025. Hence, the tax expenses for the quarter ended December 31, 2024 and quarter and year ended March 31, 2025 are not comparable with other reported periods.

b Pursuant to a change in the method of income tax calculation in USA relating to the timing of recognition of certain sales related chargeback and billback, the subsidiaries based in USA had recognized current tax liability of INR 2,689 Million with a corresponding increase in the deferred tax asset for the year ended March 31, 2024.

c Deferred tax expense for the quarter ended December 31, 2024 and year ended March 31, 2025 includes recognition of Minimum Alternate Tax [MAT] credit entitlement amounting to INR 164 Million by one of the subsidiaries of the Group. During the previous year, the same was INR 591 Million for the year ended March 31, 2024 by two subsidiaries of the Group.
 [7] a During the earlier periods, the Group had decided to close the manufacturing facilities of Nesher Pharmaceuticals (USA) LLC [Nesher] and Hercon Pharmaceuticals (USA) LLC [Hercon], both

wholly owned subsidiaries. Consequently, both Nesher and Hercon have been considered and disclosed as "Discontinued Operations" as per Ind AS 105 "Non-Current Assets held for Sale and Discontinued Operations". Accordingly, figures relating to these operations have been disclosed separately under the head "Profit/ (Loss) from the Discontinued Operations".

b During the year ended March 31, 2024, Zydus Wellness Products Limited, a subsidiary of the Group, had decided to sell assets at Sitarganj location in Uttarakhand. In accordance with Ind AS 105, such assets were classified as "Assets held for sale" from Property, Plant and Equipment and disclosed separately at the lower of their carrying values and fair values less costs to sell.

c In accordance with Ind AS 105 "Non-Current Assets held for Sale and Discontinued Operations", investment in Bayer Zydus Pharma Private Limited was classified as "Assets held for sale" accounted for using equity method and disclosed separately at the lower of its carrying value and fair value less costs to sell as at March 31, 2024.

- [8] Pursuant to the Share Purchase and Share Subscription Agreement [SPSSA] entered on August 23, 2024, Zydus Animal Health and Investments Limited, a wholly owned subsidiary of the Parent, has completed the acquisition of 50% stake of Sterling Biotech Limited [SBL] on August 29, 2024. Consequently, SBL has become a Joint Venture of the Group w.e.f. August 29, 2024. The cost of acquisition was INR 5,500 Million subject to certain adjustments with respect to cash and debt [including debt like items] as mentioned in the SPSSA. The results include the share of profits of SBL from August 29, 2024.
- [9] Pursuant to the Share Purchase Agreement [SPA] entered into by Zydus Wellness Limited [ZWL], a subsidiary of the Parent, on October 30, 2024, to acquire Naturell (Inclia) Private Limited [NIPL], ZWL has successfully completed the acquisition of NIPL on December 2, 2024. The cost of acquisition is INR 3,690 Million as upfront consideration. Over and above upfront consideration, additional consideration of INR 210 Million will be paid depending on the achievement of agreed milestones for the financial year 2024-25. The results include the operations of NIPL from December 2, 2024, with provisional purchase price allocation [PPA] figures. The PPA figures will be finalized within the measurement period, as provided by Ind AS 103.
- [10] On March 11, 2025, the Board of Directors of the Parent has approved entering into a put-option agreement and two other share purchase agreements, to acquire, directly or through its affiliates, a controlling stake i.e. 85.6% equity shares ["Block Acquisition"] of Amplitude Surgical SA, France [Amplitude] from the existing shareholders at a price of Euro 6.25 per equity share aggregating to a consideration value of Euro 256.80 Million [equivalent to INR 23,798 Million].

After conducting the mandatory information and consultation process with the Social and Economic Committee in France and obtaining a positive opinion from them, the Parent has signed the above mentioned share purchase agreement on April 25, 2025 to acquire 75.4% of the share capital of Amplitude from PAI Partners, Olivier Jallabert and other managers of Amplitude, which together with the two share purchase agreements already signed on March 11, 2025, with two minority shareholders represent 85.6% of the share capital of Amplitude. The closing of the Block Acquisition is subject to usual closing conditions [including authorization from the French Minister of Economy as part of the control of foreign investments in France] and is expected to be completed by Q3 CY25.

Subject to closing of the Block Acquisition, the Parent [or any of its affiliates] would file a mandatory simplified cash tender offer for all the remaining shares in Amplitude, at the same purchase price of Euro 6.25 per equity share of Amplitude.

The commitments to tender 4.7% of Amplitude's share capital [over and above 85.6% stake mentioned hereabove] have already been executed with other minority shareholders of Amplitude. Therefore, the Parent will be in a position to acquire more than 90% of the share capital and voting rights of Amplitude at the end of the tender offer. Post the closing of tender offer, the Parent intends to proceed with a compulsory acquisition of the remaining shares from the minority shareholders [squeeze-out] and to delist Amplitude.

[11] The figures of the quarters ended March 31, 2025 and March 31, 2024 are balancing figures between audited figures in respect of the full financial year and year to date figures upto the third quarter of the respective financial years.

[12] Figures of previous reporting periods/ year have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting periods.

[13] The detailed standalone results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com]. The summarised standalone financial results of the Company are as below:

			Rupees in Million		
	3 Months ended 31/03/2025	Preceding 3 Months ended 31/12/2024	Corresponding 3 Months ended 31/03/2024 in the previous year	Year ended 31/03/2025	Previous year ended 31/03/2024
Particulars	(Unaudited) (Refer Note-11)	(Unaudited)	(Unaudited) (Refer Note-11)	(Audited)	(Audited)
Revenue from operations	58,196	25,159	33,324	151,163	108,187
Profit before exceptional items and tax	36,747	4,972	16,935	74,447	42,484
Profit before Tax	36,747	4,972	16,849	74,447	42,398
Profit after Tax	28,137	4,706	14,052	57,749	34,415



Audited Consolidated Statement of Assets and Li		- I and the second second
	Rupees i	
Particulars	As at 31/03/2025	As at 31/03/2024
ASSETS	51/05/2025	51/05/2024
Non-current assets	C0 470	50.000
Property, plant and equipment	60,420	58,033
Capital work-in-progress	13,179	11,115
Goodwill	52,421	52,660
Other intangible assets	18,496	12,992
Intangible assets under Development	13,740	13,118
Investments accounted for using equity method	11,431	4,162
Financial assets		
Investments	4,136	5,518
Other Financial Assets	409	413
Deferred Tax Assets (Net)	23,438	16,442
Other non-current assets	2,642	2,133
Assets for Current tax (Net)	1,244	1,208
Sub-total - Non-current assets	201,556	177,794
Current assets		
Inventories	39,440	34,419
Financial assets	35,440	51,12
	40 511	2 525
Investments	48,511	2,525
Trade receivables	40,247	52,202
Cash and cash equivalents	8,268	4,130
Bank balance other than cash and cash equivalents	21,300	6,921
Loans	771	15
Other current financial assets	5,130	6,573
Other current assets	6,794	7,413
Sub-total - Current assets	170,461	114,198
Assets classified as held for sale (Refer Note-7)		816
TOTAL - ASSETS	372,017	292,808
EQUITY AND LIABILITIES		
Equity		-200
Equity share capital	1,006	1,006
Other equity	238,525	197,289
Equity attributable to equity holders of the Company	239,531	198,295
Non-Controlling Interest	24,053	22,721
Sub-total - Equity	263,584	221,016
Non-current liabilities		
Financial liabilities		
Lease liabilities	321	251
Other financial liabilities	8,722	10,542
Provisions	3,839	3,097
Deferred tax liabilities (Net)	5,126	4,465
Other Non-Current Liabilities	9	18
Sub-total - Non-current liabilities	18,017	18,373
Current liabilities		
Financial liabilities		1.1.1.1.1
Borrowings	31,695	7,686
Lease liabilities	116	105
Trade payables		
Due to Micro and Small Enterprises	974	670
Due to other than Micro and Small Enterprises	22,084	20,597
Other financial liabilities	22,213	13,891
Other current liabilities	2,663	2,780
Provisions		
	4,514	3,948
Current tax liabilities (Net)	6,157	3,720
Sub-total - Current liabilities	90,416	53,397
Liabilities directly associated with assets classified as held for sale (Refer Note-7)		22
TOTAL - EQUITY AND LIABILITES	372,017	292,808



Particulars31/02/2025at flows from operating activities:31/02/2024At flows from operating activities:31/02/2024Continuing operations00.25748.089Continuing operations [low from the?]Depreciation and Annotation anyones:9.1187.541Experitual lange (later Nules.?)2.15511.026Continuing operations and from the table (later Nules.?)(1.652)(1.652)Continuing operations and from the table (later Nules.?)(1.652)(1.652)Continuing operations of from the table (later Nules.?)(1.652)(1.652)Division from one statution of from the table (later Nules.?)(1.652)(1.652)Division from the table (later Nules.?)(1.652)(1.652)(1.652)Division from the table (later Nules.?)(1.652)(1.652)(1.652)Division from the table (later Nulls)(1.652)(1.652)(1.652)Division from the table division from the table (later Nulls)(1.652)(1.652)(1.652)Division from the table division fr	Audited Consolidated Statement of Cash Flows	Rupees in	Million	
ah How Er own operating activities: Continuing operating (left hiles of just of just velocies: Continuing operating (left hiles of just of just velocies: Continuing operating (left hiles of just of just velocies: Depresention of information operation: Depresention of information operation: Depresention of information: Depresention of information: Depresent				
Under Seiner of profer sprint number of profession (feter latter 1)	Particulars	31/03/2025	31/03/2024	
continuing operations 60,327 40,037 diputments for: 60,327 40,037 diputments for: 60,327 40,037 diputments for: 0,037 40,037 diputments for: 0,037 40,037 diputments for: 0,037 40,037 contrast operations (interport for the control (interport for control (ash flows from operating activities:			
Discreting dependence questions [even to the set of th	Profit before tax and share of profit of joint ventures	1	1.1.1.1	
Adjustments for: 9.02 48,384 Depreciation and Amortisation expense 9.158 7,641 Claim of advanced Property, Plast and Equipment [het] 0,459 (310) PT/PL gaily rapid field Note-5] 2,198 142 Claim of advanced Property, Plast and Equipment [het] 0,459 (310) Land (Ean) on subation of Property Plast and Equipments arising on Consoliation (1,372) (313) Land (Ean) on subation of Property Plast and Equipments arising on Consoliation (1,373) (883) Land (Ean) on subation of Property Plast Analysis 124 - Revision of regrotables (Plet) 223 223 During and expension wetter off 216 220 Tada 202 120 120 Provision for regrotables product expry claims and return of good (Plet of written back) 224 23 Documant (During Plast Analysis 10,024 5,487 Outful advances 10,024 5,487 Decembod (During Plast Analysis 10,024 5,487 Decembod (During Plast Analysis 10,024 5,487 Decembod (During Plast Analysis </td <td>Continuing operations</td> <td>60,267</td> <td>48,089</td> <td></td>	Continuing operations	60,267	48,089	
Adjustment for:Deprecision and Amortisation regence9,1587,64Exceptional terms (lefter folte-5)2,168142Gain) on disposed to Property, Bata and Equipment (left)(630(649)Divident income1,043(1,030)Divident income1,044(1,030)Divident income1,044(1,030)Divident income1,044(1,030)Divident income information income income income income income information income in	Discontinued operations [Refer Note-7]	-	292	
approximation and Amortisation sequence 9,188 7,641 Complication (file) (file) (file) (file) 649 (139) PTY: Gain/ gain (file) (file) (file) (file) 649 (139) Interact income (1,852) (1,863) (1,963) Interact income (1,852) (1,863) (1,863) Interact income (1,061) (1,863) (1,863) Interact income (1,061) (1,863) (1,863) Interact income (1,137) (1,863) (1,863) Interact income (1,137) (1,137) (1,137) Interact income (1,137) (1,138) (1,138) Interact income (1,138) (1,138) (1,138) Intex		60,267	48,381	
bccetonia larms [feetr Nate-5] 2,195 142 [Gain on discolar Property, Plant and Equipment [Het] (459 (130) PVTK. guinf y conft on sale of investments [Het] (459 (130) Lateset shoome (1,252) (1,263) Divided income 1,001 756 Lateset shoome 1,001 756 Ratio and analy ordit on share forward Contract value related to investment in a Jant Venture 60 (777) Exchange rate fluctuation and other related adjustments analyg on Consolidation (1,772) (788) Ansource for dividuation downees [Het or watchs adjustments analyg on Consolidation (1,772) (788) Provision for problem benefits 160 207 207 Provision for problem problem benefits 160 560 207 Provision for problem problem benefits 160 560 207 Decrease [In trade receivables 1513 160,202 7747 Total 160 160 160 160 160 160 160 160 160 160 160 160 160 160	Adjustments for:			
[Can] catagoof Preperty, Past and Equipment (Jet)(449)(130)Interest none(1,852)(1,863)Under Strand(1,97)(1,97)Under Strand(1,97)(1,97)Logd (Sing) on valuation of Prevence (ortact value related to investment in a Jont Venture(1,97)Logd (Sing) on valuation of Swap Cartinat194-Logd (Sing) on valuation of Swap Cartinat194-Dechange rafe functional and other entropic alignments arising on Carcioldation(1,779)(863)Trade receivales written off114Doubrid advances for doubling bronks (Sing)112320-Mourance for doubling bronks (Sing) (Sing) aritem of goods (Net of written back)1020Doubrid advances (Method advances (Net of written back)1020Doubrid advances (Net odvances (Net od	Depreciation and Amortisation expense	9,158	7,641	
FVTUC going vanit an sale of investments [telt](660)(402)Divident larger(1,130)(1,130)Larger Can Jan Walatian of Forward Contract value related to investment in a Joint Venture(1,01)(1,130)Larger Can Jan Walatian of Forward Contract value related to investment in a Joint Venture(1,179)(1,178)Exchanger artis functional of forward Contract value related as guitaments arising on Consolidation(1,179)(1,178)Exchanger artis functional of other related adjustments arising on Consolidation(1,179)(1,178)Large recavables withen off(1,178)(1,178)(1,178)Allowance for doubtid advances [telt of written back](1,178)(1,178)Provision for articybes bernifits(1,178)(1,178)(1,178)Provision for articybes bernifits(1,178)(1,178)(1,178)Decrease [thromaxing in tade neces/bases(1,178)(1,178)(1,178)Decrease [thromaxing in tade neces/bases(1,178)(1,178)	Exceptional items [Refer Note-5]	2,196	142	
Interest income (1,82) (1,82) Lass (Can) on valuation of forward Contract volue related to investment in a Joint Venture (0) (0) Lass (Can) on valuation of the related adjustments arising on Consolidation 1,611 756 Net Lass on Fair Valuation of Swap Contract 1,811 - Exchange rate functions and other related adjustments arising on Consolidation (1,373) (683) Taske receivables written off 1,444 - - Mournee (or doublid advances (Weld other back) 1,051 2,07 Frowise for emptype bendits 1,052 2,07 Mournee (or doublid advances (Weld other back) 1,052 2,07 Deviating profit before working capital changes 1,253 (7,472) Mournee (or doublid explaces) 1,534 (7,472) Deviating profit before working capital changes 1,534 (7,472) Deviating profit before working capital changes 1,534 (7,472) Deviating profit before working capital changes 1,534 (2,259) Deviating profit before working capital changes 1,534 (3,047) Deviating Profit before working capital changes	[Gain] on disposal of Property, Plant and Equipment [Net]	(345)	(134)	
bidden income (10) (10) (10) Loss (10) (10) (10) (10) Interest expenses 1.601 756 Net Loss on Fair Valuation of Swap Contract (11) - Expension pred Futuation and ther related alguistness string on Consolitation (11,779) (083) Table rectariables written of 144 - - Allowance for doubful advances [left of written back] 107 207 Provision for probable ponduct explin values and ream of goods [left of written back] 100,20 5,667 Operating profit bafore working asplial changes 70,471 53,848 - Decrease[] Intrade split 1,665 (15) 5,567 Operating profit bafore working asplits 1,665 (17,472) - Decrease[] Intrade splits 1,565 (7,472) - - Decrease[] Intrade splits 1,555 (13,563 - - Operating intrade splits 1,555 (13,563 - - - - - - - - - -	FVTPL gain/ profit on sale of investments [Net]	(650)	(409)	
Less (Cam) or valuation of Revend Contract value related to investment in a Joint Venture 60 (975) Interest express 1,601 756 Net Less on Fair Valuation of Swap Contract 1,911 - Exchange rate Richtation and other related adjustments arising on Consolitation 6 3 Trade receivables written of 6 3 Bobedid advances for Model ad	Interest income	(1,852)	(1,268)	
Interest 16.01 756 Pet Loss of all Velabion of Swap Contract 191 - Exchange rate fluctuation and other related adjustments arising on Consolidation (1,779) (683) Depeted realt loss on trade receivables [Net] 203 203 Depeted realt loss on trade receivables [Net] 21 28 Allowance for dubtiful advances [Net of written back] 107 207 Provision for englobule product early robins and return of goods [Net of written back] 603 170 Total 112,204 5,467 Operating profit before working acpial changes 10,471 53,848 Operating profit before working capial changes 11,513 (7,472) Decrease [In Intrades publies 5,111 335 Decrease [Intrades in Intrades publies 6,760 (7,757) Total 15,315 (30,272) Carl generating activities 9,061 (12,255) Horease [In the publies 5,111 335 Total 15,315 (30,272) Total (12,255) (7,757) Total (12,25	Dividend income	(10)	(13)	
Net Loss on fair Valuation of Swap Contract 191 - Exchange rate Richtation and other related adjustments ating on Consolitation (1,373) (683) Trade receivables written off 6 3 Doubtid advances written off 144 - Monance for doubtid advances (Feld Written back) 121 28 Provision for probable product eacy (Feld written back) 10224 5,467 Total 10224 5,467 Doubtid before working capital changes 70,471 5,3848 Decesses (Increase) in trade receivables 11,029 10,224 Decesses (Increase) in trade receivables 11,029 10,241 Decesses (Increase) in trade receivables 11,109 11,109 Increase in other increase in trade receivables 5,111 355 Total 15,315 0,027 Darge entation from operators 5,766 4,421 Increase in other increase in other excessible accel (including psyment towards 11,109 (1,255) Decesses (Increase) active decessible accel (including basets 5,141 2,27 Total 6,777 <td< td=""><td>Loss/ [Gain] on valuation of Forward Contract value related to investment in a Joint Venture</td><td>60</td><td>(976)</td><td></td></td<>	Loss/ [Gain] on valuation of Forward Contract value related to investment in a Joint Venture	60	(976)	
bxtange rate fluctuation and other related adjustments arising on Consolidation (1,379) (63) Totale cercitables within of 6 3 Expected craft iss on hade receivables [Vet) 233 233 Doubfild advances [Vet of written back] 124 24 Provision for probable product sophy claims and return of goods [Vet of written back] 633 1107 Total 10,294 5,467 Operating proft before working capital changes 70,471 53,488 Maystments for: 12,558 (7,472) Decrease(] Increase] In there results 1,109 (1,119) Increase (Decrease) In there sates 1,109 (1,129) Increase (Increase) In there sates 5,111 355 Total 55,766 44,421 Increase In there itabilities 6,7767 31,983 Aflows form increase 6,6740 - Total 6,8766 4,4231 Increase In there approxing activities 5,111 395 Total 5,5766 44,421 Increase In theretapproxing activities 6,7767	Interest expenses	1,601	756	
Tade creace/disc written off 6 3 Doubtify dawances written off 233 233 Adwance for doubtif dawances (let of written back) 124 24 Provision for produce be product sepiry claims and return of goods [let of written back] 167 207 Provision for produce be product sepiry claims and return of goods [let of written back] 102.04 55.467 Operating profit before working capital changes 70,471 53,848 Adjustments for Doubtify 100.204 55.467 Decrease/[Drorseal] in trade receivables 12,535 (7,472) Increase/[Drorseal] in trade receivables 53.35 (0002) Decrease/[Drorseal] in trade receivables 55.315 (0002) Decrease/[Drorseal] in trade receivables 67,767 31,563 Approache form investing activities: 67,309 12,2559 Hords and form activities 630 550 P	Net Loss on Fair Valuation of Swap Contract	191	-	
Task creaces/dec written off 6 3 Doubfill dawances written off 233 344		(1,379)	(883)	
boddfild advances written off 144			16 2.64	
bodyful Javance; written off 144 Allowarce for doubled Javance; [Incel written back] 167 287 Provision for probyce benefits 167 287 Provision for probyce benefits 102.44 58.447 Total 102.44 58.447 Operating profit before working capital changes 70,471 53.848 Applications for 102.544 53.848 Applications for 125.335 (7,472) Increase (Increase) In trade receivables 5.911 3553 Construct (Increase) In trade receivables 5.911 3553 Total 5.913 (10,027) (26,469) Total 11.1 355 11.100 (11,111) Total 15.315 (10,027) (26,469) Total 15.315 (11,122) (11,126) (11,126) Provesting racin (Increase) in balan exclument and intangable assets (Including payment towards) (17,126) (10,466) Provesting racin (Including advinitions and explanment and intangable assets (Including advinitions advinitions) (11,126) (11,126)	Expected credit loss on trade receivables [Net]	293	203	
Allowance for doubtil advances [rice of written back] 21 28 Provision for probable product expiry claims and return of goods [Net of written back] 603 107 Total 10204 5.467 Operating profit before working capital changes 70,471 53,848 Operating profit before working capital changes 10,524 5.467 Decreased [Increase] in rule receivables 11,59 (7,472) Decreased [Increase] in rule receivables 11,59 (7,472) Increase [Increase] in rule receivables 11,53 (4,449) (20) Decreased [Increase] in rule receivables 5,11 355 (9,027) Total 15,315 (9,027) 31,363 (9,027) And encertal from operations 6,76 44,821 (17,16) (17,16) (10,17) Increase in onit devices (rom rule explorement and intangible assets [Including payment to acquisition of buint control 6,768 - - Protease from sources in transpite asset under development and capital advances] (17,16) (9,066) - Protease from active investments 5,4 227 -				
provision for employee banefits 107 207 Provision for probable product explay claims and return of goods [Net of written back] 10.204 5.5.467 Operating profits before working capital changes 70,471 53.848 Mijutments for: 12.558 7(7,472) Decrease] in trade receivables (4,449) (20) Decrease] in trade receivables (4,449) (20) Decrease] (Increase] in trade receivables (4,449) (20) Decrease (Increase) in trade receivables (4,449) (20) Decrease (Increase) in trade receivables (4,449) (20) Decrease (Increase) in trade receivables (5,111) (5,112) Decrease (Increase) in trade receivables (5,112) (9,026) Increase (Internet) (10,12) (10,12) (9,026) Stores from investing activities: (11,12) (11,12) (11,12) Proceeds for on operating activities: (11,12) (9,066) Proceeds for on operating activities (12,25) (10,07) Proceeds for on operating activities (12,45) (11,12) Proce			28	
provisitio produble product expiry claims and return of goods [Net of written back] 6.03 1.70 Total 10.204 5.467 Operating profit before working capital changes 70,471 53,848 Operating [Increase] in trade neceivables 12,558 (7,472) Encrease/ [Increase] in trade neceivables 12,558 (7,472) Increase in other sets 1,03 (1,144) Increase in other sets 11,03 (1,144) Increase in other sets 5,011 5587 Total 15,315 (0,027) State particitate from operations 67,767 31,903 Increase in other products 67,767 31,903 Proceeds from operating activities 67,767 31,903 Proceeds from operating activities 67,767 31,903 Proceeds from operating activities 67,701 31,903 Proceeds from operating activities 67,701 31,903 Proceeds from operating activities 67,701 31,903 Proceeds from operating activities 63,690 7,7201 Proceeds from operating activitie				
Total 10.204 5.467 Operating profit before working capital changes 70,471 53,848 Adjustments for: 70,471 53,848 Decreased (Increase) in trade receivables (4,449) (20) Decreased (Increase) in trade receivables (4,449) (20) Decreased (Increase) in trade receivables (4,449) (20) Increase (Decrease) in trade receivables 5111 555 Total 55,151 (9,027) Carl generated from operations 68,766 (44,421) Increase (Decrease) in trade regiment and intragible assets (including payment travards 67,767 31,963 More trans intragers intradig trasset under development and intragible assets (including payment travards) (7,125) (9,066) Proceeds for on reduction of burienses (3,600) (7,201) Payment for acquisition of burienses (3,600) (7,201) Proceeds for on reduction of traverses 900 550 Proceeds for on reduction of deposition on considered as cash and cash equivalents (1,456) (3,570) Drocease for finate buriens in a joint venture (45,536) 4,077 (4,535) <td< td=""><td></td><td></td><td>22.1</td><td></td></td<>			22.1	
Operating profit before working capital changes 70,471 53,848 Increase] In trade receivables 12,558 (7,472) Increase] In inder receivables (2,449) (2,00) Decrease/ [Increase] in trade payables 966 (4,449) Increase in that do payables 966 (4,449) Increase in that do payables 966 (4,469) Increase in that do payables 966 (4,469) Capital end from operations 85,786 (4,821) Increase in that end payables 67,767 31,963 Proceeds from starting activities: 67,767 31,963 Proceeds from starting activities: 67,767 31,963 Proceeds from starting downlesses: (3,600) (7,201) Payment for acquisition of bint control (6,766) - Proceeds from sale of investments in a joint venture 185 - Proceeds from sale of investments in joint venture 185 - Proceeds from sale of investments in joint venture 185 - Proceeds from sale of investments in low themating downlesses (3,600) - <				
adjustments for:Image: consider receivablesImage: consider receivabl				
Decrease/ [Increase] in trade receivables 12,558 (7,472) [Increase] in network/se (4,449) (20) Decrease/ [Increase] in take payables 966 (476) Increase (Increase) in take payables 956 (476) Increase (Increase) in take payables 956 (476) Total 15,155 (9,027) Cash generated from operations (55,766 (44,82) Increase in third receivable activities: 67,767 31,963 Purchase of property, plant and equipment and intangible assets (including payment towards (17,126) (9,066) Proceeds from sele of property, plant and equipment and intangible assets 514 237 Payment for acquisition of business (6,760) (5,060) Proceeds from relegend from operations (17,126) (9,066) Proceeds from relegend from operations (17,126) (9,066) Proceeds from relegend from operations (17,126) (9,066) Proceeds from relegend from operations (17,126) (10,072) Proceeds from sele of Investments in a joint venture 185 - Proceeds from sel				
Invertories (4,449) (20) Decrease (Inverses) in trade payables 1,49 (4,44) Increase (Inverses) in trade payables 5,111 355 Total 15,215 (20,27) Cash generated from operations 85,766 44,821 Increase of property, plant and equipment and intengible assets (including payment towards equipation of businesses 67,767 31,953 Parchase of property, plant and equipment and intengible assets (including payment tor acquisition of businesses 514 237 Payment for acquisition of for on-convertible debentures 500 7,701) Proceeds from sale of property, plant and equipment and intengible assets 514 237 Proceeds from sale of property, plant and equipment and intengible assets 514 237 Proceeds from sale of property, plant and equipment and intengible assets 514 237 Proceeds from sale of non-convertible debentures 900 550 Proceeds from sale of non-convertible debentures 15 - Purchase of non corrent investments (425) (4,077) Proceeds from sale of non corrent investments (425) (4,072) <t< td=""><td></td><td>12,558</td><td>(7.472)</td><td></td></t<>		12,558	(7.472)	
Decrease/ [Increase] in take payables 1,09 (1,414) Increase in other labilities 5,111 355 Total 15,315 (0,022) Cash generated from operations 85,786 44,821 Increase in other labilities 67,777 31,963 Purchase of propersting activities: 67,777 31,963 Purchase of propersty, plant and equipment and intangible assets [Including payment towards 67,767 31,963 Purchase of property, plant and equipment and intangible assets 514 237 Proceeds from relegation of businesses (3,690) (7,720) Proceeds from relegation of hoursetses (3,690) (7,720) Proceeds from relegation of hoursetses (43,560) (3,578) Proceeds from relegation of noursets a joint venture 1,260 - Proceeds from relegation of noursets (het) (45,356) (4,772) Proceeds from relegation of current investments in a joint venture 1,260 - Proceeds from relegation of current investments in a joint venture (45,356) (4,772) Proceeds from relegation of current investments in a joint venture (45,356)		1		
Increase (Decrease) in trade payables 986 (476) Increase in other liabilities 5111 355 Total 15,315 (9,027) Cash generated from operations 67,767 31,963 Income taxes paid [Net of refunds] (17,125) (9,066) Purchase of property, plant and equipment and intangible assets (Including payment towards 67,767 31,963 At Mose's from investing activities: (17,125) (9,066) Purchase of property, plant and equipment and intangible assets (3,690) (7,201) Payment for acquisition of businesses 3(3,600) (7,201) Proceeds from asle of property, plant and equipment and intangible assets (3,678) - Proceeds from asle of investments in a joint venture 185 - Purchase of non current investments (42,55) (1,067) Proceeds from asle of non current investments (43,56) (3,578) Current torsetimets (in redemption of current investments (Net) (43,55) (4,772) Proceeds from asle of non current investments (43,55) (4,772) Investments in/ redemption of current investments (Net) (4				
Increase in other liabilities 5.111 355 Total 15.315 (9.027) Cash generated from operations 67.767 31.963 Purchase of property, plant and equipment and intangible assets [including payment towards 67.767 31.963 Purchase of property, plant and equipment and intangible assets [including payment towards 67.767 31.963 Proceeds from sale of property, plant and equipment and intangible assets (17.126) (9.066) Proceeds from sale of property, plant and equipment and intangible assets (3.690) (7.201) Payment for acquisition of businesses (3.690) (7.201) Payment for acquisition of businesses (45.755) (4.067) Proceeds from ale of investments in a joint venture 185 - Proceeds from aleadores (including flow denotes) into considered as cash and cash equivalents (17.265) (4.725) Proceeds from aleadores (including flow denotes) into considered as cash and cash equivalents (17.750) (45.356) 4.077 Unreading flow theoreties (45.356) (4.772) (45.356) 4.077 Unreading activities (47.572) (4.672) (4.672)				
Total15.315(9,027)Cash generated from operations85,78644,821Income taxes paid [Net of refunds](15,019)(12,258)Nuches taxes paid (Net or refunds)67,76731,963Wet cash from operating activities:67,76731,963Purchase of property, plant and equipment and intangible assets (including payment towards)(17,126)(9,066)Proceeds from sale of property, plant and equipment and intangible assets514237Payment for acquisition of joint control(6,706)-Proceeds from refemption of non-convertible debentures900550Proceeds from acted investments in a joint venture185-Purchase of non current investments(14,356)(3,576)Purchase of non current investments(14,356)(3,576)Purchase of non current investments [Net](45,353)4,077Change in Bank balances (including fixed deposits) not considered as cash and cash equivalents(14,356)(3,576)Change in Bank balances (including fixed deposits) not considered as cash and cash equivalents(14,356)(3,576)Underd arcevized18151,27410Dividend received18151,27410Dividend received18151,27410Dividend received18151,27410Dividend received1851,423(14,752)sh flows from financing activities:(83,723)(14,752)sh flows from financing activities20,424(14Interest paid(895)<			and the second	
Cach generated from operating (Net of refunds) 87,66 44,821 Income taxes paid [Net of refunds] 12,2593 ket cash from operating activities: 7,767 31,663 Purchese of property, phart and equipment and intangible assets [including payment towards 12,259 capilal work-in-progress, intangible asset under development and capital advances] 11,71,20 (9,066) Proceeds from sale of property, plant and equipment and intangible assets 31,603 (7,201) Payment for acquisition of businesses (3,690) (7,201) Proceeds from sale of investiments in a joint venture 185 - Purchase of noncurrent investments (425) (1,067) Proceeds from alce of investiments in a joint considered as cash and cash equivalents (43,506) (3,578) Unvestiments in y contrait investments (425) (4,5336) (4,5736) Proceeds from alce of investiming activities (45,536) (4,5736) - Universtime strip (Ref Proceeds (regayment)) (45,536) (4,5736) - Dividend received 10 13 - Dividend received 10 13 - Brows from financing activities: (45,236) (4,5136) - Repayment of non current investments (2,027) - (7,250) <				
Income taxes pidl [Net of refunds](12,859)Net cash from operating activities67,76731,963Purchase of property, plant and equipment and intangible assets [including payment towardsapplal work-hopperss, intangible asset under development and capital advances](17,125)(9,066)Proceeds from sale of property, plant and equipment and intangible assets514237Payment for acquisition of but control(6,708)-Proceeds from refemption of non-convertible debentures900550Proceeds from acte of investments in a joint venture185-Purchase of non current investments(425)(1,067)Proceeds from acte of investments ing fixed deposits) not considered as cash and cash equivalents(43,356)(3,376)Proceeds from action of current investments [Net](45,336)4,077Loans to others(68,7723)(14,752)And from externing activities(83,723)(14,752)And from externing fixed deposits) not considered as cash and cash equivalents(14,356)(3,376)Dividend from theore introset ments [Net](83,723)(14,752)And from theore introset ments(82,723)(14,752)And from theore introset ments(82,723)(14,752)And from theore introset ments(3,202)(5,200)Unrest to others(2,202)(3,202)Dividend for adjusties(3,626)(4,130)And the deprinting of the year4,136(5,77)And cash equivalents at the edo of the year4,136(5,77)<				
Net cash from operating activities: 67,767 31,963 sh flows from investing activities: (7,125) (9,066) capial work-in-progress, intangible assets under development and capital advances] (7,125) (9,066) Porceeds from sale of property, plant and equipment and intangible assets (3,690) (7,201) Payment for acquisition of joint control (6,708) - Proceeds from sale of investments in a joint venture 185 - Proceeds from sale of non-convertible debentures 900 550 Proceeds from sale of non-convertible debentures 100 - Proceeds from sale of non-convertible debentures (425) (1,067) Proceeds from sale of non-convertible debentures 100 - Proceeds from sale of non-current investments [Net] (43,366) (3,578) Investing activities (14,366) (3,578) Investing activities (14,366) (3,578) Dividend received 10 13 Net cash [used in] investing activities (14,3752) (14,752) Sh flows from financing activities - (627) Current borrowings (Net - Proceeds (repayment)) 24,020 (3,102) Buyback of equity shares [including tax and transaction costs] - (7,250) Lease liabilities [가슴 사장 가가 잘 다 나라에 다 가게 하는 것 같아.	17 million 19	the second se	
sh flows from investing activities: Image: State		and the second sec		
Purchase of property, plant and equipment and intangible assets (including payment towards. (17,126) capital work-in-progress, intangible assets under development and capital advances] (17,126) Payment for acquisition of businesses 514 237 Payment for acquisition of businesses 500 550 Payment for acquisition of joint control (6,708) - Proceeds from sale of investments in a joint venture 185 - Purchase of non current investments (425) (1,067) Proceeds from sale of investments in a joint considered as cash and cash equivalents (43,56) - Proceeds from sale of non current investments [Net] (45,336) 4,077 Loans to others (7,250) - Investments in jrinderingthing activities (83,723) (14,752) Interest received 1,815 1,227 Ovidend received 10 13 Net cash (luced in] investing activities (83,723) (14,752) Repayment of non current borrowings - (827) Current borrowings [Net - Proceeds/ (repayment)] 24,020 (3,102) Bybrack of equipy shares [including tax and transaction costs] 2,020 (4,13) Underst paid (3,022) (4,23) Used in form chan og activities 20,142		07,707	31,903	
capital work-in-progress, intangible asset under development and capital advances] (17,126) (9,065) Proceeds from sale of property, plant and equipment and intangible assets 514 237 Payment for acquisition of buintsesses (3,600) (7,201) Payment for acquisition of point control (6,708) - Proceeds from redemption of non-convertible debentures 900 550 Proceeds from sale of investments in a joint venture 185 - Purchase of non current investments 1,2260 - Proceeds from sale of non-current investments (4,356) (4,077) Change in Bank balances (including fixed deposits) not considered as cash and cash equivalents (4,366) (7,210) Drivident received 1,815 1,274 - Orieden treewide 10 13 - Net cash (used in] investing activities (83,723) (14,752) - Subjack of equity shares [including tax and transaction costs] - (7,250) - Current borrowings [Net - Proceeds/ (repayment)] 24,020 (3,102) - Buyback of equity shares [including tax and transaction costs] - - - Net cash		18 (F)		
Proceeds from sale of property, plant and equipment and intangible assets.514237Payment for acquisition of businesses(3,660)(7,201)Payment for acquisition of non-convertible debentures900550Proceeds from sale of non current investments(425)(1,067)Proceeds from sale of non current investments(425)(1,067)Proceeds from sale of non current investments(43,56)(3,578)Change in Bank balances (including fixed deposits) not considered as cash and cash equivalents(43,56)(3,578)Change in Bank balances (including fixed deposits) not considered as cash and cash equivalents(43,56)(3,578)Change in Bank balances (including fixed deposits) not considered as cash and cash equivalents(41,355)(4,077)Leans to others(41,355)(4,077)(45,336)(4,077)Dividend received1,8151,2741013Dividend received1013(4,752)(4,752)Biflows from financing activities:-(827)(24,020)Current borrowings [Net - Proceeds/ (repayment)]24,020(3,102)Biyback of equity Shares [including tax and transaction costs]-(7,720)Lease labilities [Net](20,22)(6,210)Wet cash from (Lsed in Jinancing activities20,142(17,788)Lease labilities [Net](21,23)(4,578)Interest paid(895)(413)Dividends paid(20,22)(6,210)Lease labilities [Net](21,42)(231)Interest paid<		(17 170)	(0.000)	
Payment for acquisition of businesses(3,690)(7,201)Payment for acquisition of joint control(6,708)-Proceeds from convertible debentures900550Proceeds from sale of investments in a joint venture185-Purchase of non current investments(425)(1,067)Proceeds from sale of non current investments(14,366)(3,578)Change in Bank balances (including fixed deposits) not considered as cash and cash equivalents(14,366)(3,578)Cinvestments in/ redemption of current investments [Net](45,336)4,077Lones to others(755)9Interest received113Dividend received113Vet cash [used in] investing activities:(83,722)(14,752)sh flows from financing activities:-(827)Current borrowings (Met - Proceeds/ (repayment))24,020(3,102)Dividend paid(695)(413)Dividends paid(3,025)(6,210)Net cash lucid in] financing activities4,186titnerest (Idcorease) in cash and cash equivalents4,166Sh and cash equivalents of the acquired subsidiaries166et of foreign exchange rate changes on cash and cash equivalents(214)sh and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:ary of Cash and cash equivalents8,268sh and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:ary of Cash and cash equivalents8,268sh and cash				
Payment for acquisition of joint control(6,708)-Proceeds from redemption of non-convertible debentures900550Proceeds from sale of investments in a joint venture(425)(1,067)Purchase of non current investments(425)(1,067)Change in Bank balances (including fixed deposits) not considered as cash and cash equivalents(1,366)(3,578)Cinvestments in/ redemption of current investments [Net](45,336)(4,077)Loans to others(1,456)(3,578)Cinvestments in/ redemption of current investments [Net](1,456)(1,172)Loans to others(1,456)(1,172)Interest received1013Net cash [used in] investing activities:(83,723)(1,4752)Binows from financing activities:(1,250)(1,250)Repayment of non current borrowings-(827)Current borrowings [Net - Proceeds/ (repayment)]24,020(3,102)Buyback of equity shares [including tax and transaction costs]-(7,250)Interest paid(3,025)(6,210)Dividends paid(3,025)(6,210)Net cash requivalents at the beginning of the year4,1304,878sh and cash equivalents at the equivalents(2,142)(2,17,788)st correst [Convinges on Cash and cash equivalents(2,142)(2,17)sh and cash equivalents at the end of the year4,1304,878sh and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 morths:31/03/2024at and equivalents fits,		And the second sec	and the second second	
Proceeds from redemption of non-convertible debentures900550Proceeds from sale of investments in a joint venture185-Proceeds from sale of non current investments(425)(1,667)Proceeds from sale of non current investments1,260-Change in Bank balances (including fixed deposits) not considered as cash and cash equivalents(14,366)(3,578)(Investments in) / redemption of current investments [Net](45,336)4,077Loans to others(756)9Interest received1013Net cash [used in] investing activities(83,723)(14,752)Sh flows from financing activities:(83,723)(14,752)Buyback of equity shares [Including fixe and transaction costs]-(7250)Lease iabilities [Net]24,020(3,102)Buyback of equity shares [Including tax and transaction costs]-(72,720)Lease iabilities [Net](42,53)(413)Obvidend received1013Dividend spaid(895)(413)Dividends paid(3,025)(6,210)Net cash from/ [used in] financing activities20,142(17,788)et increase/ [decrease] in cash and cash equivalents4,1804,878sh and cash equivalents of the squired subsidiaries10660et of foreign exchange rate changes on Cash and cash equivalents(214)(231)sh and cash equivalents at the end of the year8,2684,130nal Information:31/03/202431/03/202431/03/2024at an			(7,201)	
Proceeds from sale of investments in a joint venture185-Purchase of non current investments(14,36)(1,067)Proceeds from sale of non current investments(14,360)(3,578)Change in Bank balances (including fixed deposits) not considered as cash and cash equivalents(14,360)(3,578)(Investments in/) redemption of current investments [Net](45,336)(4,077)Loans to others(756)91Interest received1013Net cash (used in) investing activities:(83,723)(14,752)Repayment of non current borrowings-(827)Current borrowings [Net - Proceeds/ (repayment)]24,020(3,102)Byback of equity shares [including tax and transaction costs]-(7,780)Lease liabilities [Net]421414Interest paid(3,025)(6,210)Net cash nom/ [used in] financing activities:20,142(17,788)It increase/ [decrease] in cash and cash equivalents4,1304,878sh and cash equivalents at the beginning of the year4,1304,878sh and cash equivalents at the end of the year8,2684,130nal Information:31/03/202531/03/2024sh and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:31/03/2024sh and cash equivalents at the end of the year8,2684,130sh and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:31/03/2024sh and cash equivalents8,2684,130 <td></td> <td></td> <td>•</td> <td></td>			•	
Purchase of non current investments(425)(1,067)Proceeds from sale of non current investments1,260-Change in Bank balances (including fixed deposits) not considered as cash and cash equivalents(14,366)(3,578)(Investments in]/ redemption of current investments [Net](756)9Interest received1013Dividend received1013Net cash [used in] investing activities(83,723)(14,752)sh flows from financing activities:(83,723)(14,752)sh payment of non current borrowings-(827)Current borrowings [Net - Proceeds/ (repayment)]24,020(3,102)Buyback of equity shares [including tax and transaction costs]-(7,250)Lease liabilities [Net]4214Interest paid(895)(f13)Dividend spaid(3,025)(6,210)Net cash from/ [used in] financing activities4,136(577)sh and cash equivalents at the beginning of the year4,1304,678sh and cash equivalents at the beginning of the year8,2684,130and lanformation:-21,3005,921and act equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:31/03/2024sh and cash equivalents8,2684,130h and cash equivalents at the end of the year8,2684,130h and cash equivalents21,3006,521rerest paid21,3006,521rerest paid8,2684,130h and cash equivalent			550	
Proceeds from sale of non current investments1,260Change in Bank balances (including fixed deposits) not considered as cash and cash equivalents(14,366)(3,578)(45,333)(4,077Consor to others(18,155)Interest received1,815Dividend received10Net cash [used in] investing activities(83,723)Sh flows from financing activities:-Repayment of non current borrowings-Current borrowings [Net - Proceeds/ (repayment)]24,020Buyback of equity shares [including tax and transaction costs]-Current borrowings [Net - Proceeds/ (repayment)](3,023)Buyback of equity shares [including tax and transaction costs]-It interest paid(3,023)Ovidends paid(3,025)Sh and cash equivalents at the beginning of the year4,130Sh and cash equivalents at the beginning of the year4,130Sh and cash equivalents at the end of the year31/03/2024sh and cash equivalents at the end of the year8,268sh and cash equivalents at the end of the year4,130sh and cash equivalents8,268sh and cash equivalents21,300sh and cash equivalents8,268sh and cash equivalents4,130sh and cash equivalents8,268sh and cash equivalents6,921rent Investments21,300sh and cash equivalents21,300sh and cash equivalents8,268sh and cash equivalents8,268sh and cash equivalents	이 있는 것 같은 것 같			
Change in Bank balances (including fixed deposits) not considered as cash and cash equivalents(14,366)(3,578)(Investments in// redemption of current investments [Net](45,336)4,077Loans to others(756)9Interest received1013Dividend received1013Net cash (used in) investing activities(83,723)(14,752)sh flows from financing activities:(83,723)(14,752)Repayment of non current borrowings-(827)Current borrowings [Net - Proceeds/ (repayment)]24,020(3,102)Buyback of equity shares [including tax and transaction costs]-(7,250)Lease liabilities [Net]4214Interest paid(895)(413)Oividends paid(3,025)(6,210)Net cash from/ [used in] financing activities20,142(17,788)ti crease [dicturated subsidiaries4,186(577)sh and cash equivalents of the acquired subsidiaries16660ect of foreign exchange rate changes on Cash and cash equivalents(214)(231)sh and cash equivalents at the end of the year8,2684,130and Information:-3316vert of cash and cash equivalents8,2684,130nc adsh equivalents8,2684,130at ads active equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:316urar31652,13052,525ed Deposits more than 12 month's maturity31			(1,067)	
[Investments in]/ redemption of current investments [Net] (45,336) 4,077 Loans to others (756) 9 Interest received 10 13 Net cash [used in] investing activities (83,723) (14,752) sh flows from financing activities: (827) Current borrowings - (827) Current borrowings [Net - Proceeds/ (repayment)] 24,020 (3,102) Buyback of equity shares [including tax and transaction costs] - (7,250) Lease labilities [Net] 42 14 Interest paid (895) (413) Dividend received 3(3,025) (6,210) Net cash from/ [used in] financing activities 4,186 (577) sh and cash equivalents at the beginning of the year 4,130 4,878 sh and cash equivalents of the acquired subsidiaries 166 60 ect of foreign exchange rate changes on Cash and cash equivalents (2,26) 4,130 sh and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months: 103/03/0224 sh and cash equivalents 8,268 4,130 nk balance other than cash and cash equivalents 8,268				
Loans to others(756)9Interest received1,8151,274Dividend received1013Net cash [used in] Investing activities(83,723)(14,752)sh flows from financing activities:(83,723)(14,752)sh flows from financing activities:(83,723)(14,752)sh flows from financing activities:(827)(827)Current borrowings [Net - Proceeds/ (repayment)]24,020(3,102)Bybback of equity shares [including tax and transaction costs]-(7,250)Lease liabilities [Net]4214Interest paid(895)(413)Dividends paid(3,025)(6,210)Net cash from/ [used in] financing activities20,142(17,788)et increase/ [decrease] in cash and cash equivalents20,142(17,788)sh and cash equivalents of the beginning of the year16660sh and cash equivalents of the acquired subsidiaries16660et of foreign exchange rate changes on Cash and cash equivalents21,40221,4130sh and cash equivalents at the end of the year8,2684,130anal Information:31/03/202431/03/2024ary of Cash and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:31/03/2024and cash equivalents8,2684,130nk balance other than cash and cash equivalents8,2684,130nk balance other than cash and cash equivalents21,3006,921rent Investments8,2684,1306,921 </td <td></td> <td></td> <td></td> <td></td>				
Interest received1,8151,274Dividend received1013Net cash [used in] investing activities:(83,723)(14,752)Repayment of non current borrowings-(827)Current borrowings [Net - Proceeds/ (repayment)]24,020(3,102)Buyback of equity shares [including tax and transaction costs]-(7,250)Lease labilities [Net]4214Interest paid(895)(413)Dividends paid(3,025)(6,210)Net cash from/ [used in] financing activities20,142(17,788)Lt increase [decrease] in cash and cash equivalents4,186(577)sh and cash equivalents of the acquired subsidiaries16660ect of foreign exchange rate changes on Cash and cash equivalents(214)(231)sh and cash equivalents at the end of the year8,2684,130intar sup of Cash and cash equivalents31/03/202531/03/2024sh and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:31/03/2024ulars31/03/202531/03/2024sh ad cash equivalents8,2684,130nk balance other than cash and cash equivalents21,3006,921rent Investments21,3006,921ed Deposits more than 12 month's maturity316				
Dividend received1013Net cash [used in] investing activities(83,723)(14,752)sh flows from financing activities:(83,723)(14,752)sh flows from financing activities:-(827)Current borrowings [Net - Proceeds/ (repayment)]24,020(3,102)Buyback of equity shares [including tax and transaction costs]-(7,250)Lease liabilities [Net]4214Interest paid(895)(413)Dividends paid(3,025)(6,210)Net cash from/ [used in] financing activities20,142(17,788)±t increase/ [decrease] in cash and cash equivalents4,186(577)sh and cash equivalents of the acquired subsidiaries16660ect of foreign exchange rate changes on Cash and cash equivalents(214)(231)sh and cash equivalents at the end of the year8,2684,130and Information:31/03/202531/03/2024and cash equivalents at the end of the year8,2684,130and cash equivalents at the end of the year8,2684,130and cash equivalents at the end of the year8,2684,130and cash equivalents21,3006,921rent Investments21,3006,921net trans equivalents21,3006,921net bert than cash and cash equivalents21,3006,921ed Deposits more than 12 month's maturity316	Loans to others			
Net cash [used in] investing activities(83,723)(14,752)sh flows from financing activities:-(827)Repayment of non current borrowings-(827)Current borrowings [Net - Proceeds/ (repayment)]24,020(3,102)Buyback of equity shares [including tax and transaction costs]-(7,250)Lease liabilities [Net]4214Interest paid(895)(413)Dividends paid(3,025)(6,210)Net cash from/ [used in] financing activities4,186(577)sh and cash equivalents at the beginning of the year4,1304,878sh and cash equivalents at the beginning of the year4,1304,878sh and cash equivalents at the end of the year8,2684,130nal Information:	Interest received			
sh flows from financing activities: Repayment of non current borrowings-(827)Current borrowings [Net - Proceeds/ (repayment)]24,020(3,102)Buyback of equity shares [including tax and transaction costs]-(7,250)Lease liabilities [Net]4214Interest paid(3)025(6,210)Dividends paid(3)025(6,210)Net cash from/ [used in] financing activities20,142(17,788)et and cash equivalents at the beginning of the year4,1304,878sh and cash equivalents of the acquired subsidiaries16660ect of foreign exchange rate changes on Cash and cash equivalents(214)(231)sh and cash equivalents at the end of the year8,2684,130and rash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:31/03/2024ulars31/03/202531/03/2024sh and cash equivalents21,3006,921and cash equivalents fit the acquired subsidiaries316	Dividend received			
Repayment of non current borrowings-(827)Current borrowings [Net - Proceeds/ (repayment)]24,020(3,102)Buyback of equity shares [including tax and transaction costs]-(7,250)Lease liabilities [Net]4214Interest paid(895)(6,210)Net cash from/ [used in] financing activities20,142(17,788)Let cash equivalents at the beginning of the year4,1304,878sh and cash equivalents of the acquired subsidiaries16660ect of foreign exchange rate changes on Cash and cash equivalents(214)(231)sh and cash equivalents at the end of the year8,2684,130and cash equivalents at the end of the year8,2684,130sh and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:31/03/2025ulars31/03/202531/03/2024sh and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:21,330and cash equivalents for the year31/03/202531/03/2024sh and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:31/03/2025ulars31/03/202531/03/2024sh and cash equivalents8,2684,130and cash equivalents8,2684,130sh and cash equivalents8,2684,130and cash equivalents8,2684,130and cash equivalents8,2684,130sh and cash equivalents8,2684,230sh and cash equivalents8,	Net cash [used in] investing activities	(83,723)	(14,752)	
Current borrowings [Net - Proceeds/ (repayment)]24,020(3,102)Buyback of equity shares [including tax and transaction costs]-(7,250)Lease liabilities [Net]4214Interest paid(895)(413)Dividends paid(3,022)(6,210)Net cash from/ [used in] financing activities20,142(17,788)st increase/ [decrease] in cash and cash equivalents4,186(577)sh and cash equivalents at the beginning of the year4,1304,878sh and cash equivalents of the acquired subsidiaries16660ect of foreign exchange rate changes on Cash and cash equivalents(214)(231)sh and cash equivalents at the end of the year8,2684,130nal Information:31/03/202531/03/2024sh and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:31/03/2024ulars31/03/202531/03/2024sh and cash equivalents8,2684,130not cash equivalents8,2684,130not cash equivalents8,2684,130not cash equivalents8,2684,130not cash equivalents8,2684,130not cash equivalents48,5112,525ed Deposits more than 12 month's maturity316	sh flows from financing activities:			
Buyback of equity shares [including tax and transaction costs] - (7,250) Lease liabilities [Net] 42 14 Interest paid (895) (413) Dividends paid (3,025) (6,210) Net cash from/ [used in] financing activities 20,142 (17,788) et increase/ [decrease] in cash and cash equivalents 4,186 (577) sh and cash equivalents at the beginning of the year 4,130 4,878 sh and cash equivalents of the acquired subsidiaries 166 60 ect of foreign exchange rate changes on Cash and cash equivalents (214) (231) sh and cash equivalents at the end of the year 8,268 4,130 nal Information: 31/03/2025 31/03/2024 sh and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months: 31/03/2024 wild balance other than cash and cash equivalents 8,268 4,130 nk balance other than cash and cash equivalents 21,300 6,921 nrent Investments 21,300 6,921 ed Deposits more than 12 month's maturity 3 16	Repayment of non current borrowings		(827)	
Lease liabilities [Net]4214Interest paid(895)(413)Dividends paid(3,025)(6,210)Net cash from/ [used in] financing activities20,142(17,788)et increase/ [decrease] in cash and cash equivalents4,186(577)sh and cash equivalents at the beginning of the year4,1304,878sh and cash equivalents of the acquired subsidiaries16660ect of foreign exchange rate changes on Cash and cash equivalents(214)(231)sh and cash equivalents at the end of the year8,2684,130inal Information:31/03/202531/03/2024ary of Cash and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:31/03/2024ulars8,2684,130sh and cash equivalents8,2684,130ink balance other than cash and cash equivalents21,3006,921rrent Investments21,3006,921ed Deposits more than 12 month's maturity316	Current borrowings [Net - Proceeds/ (repayment)]	24,020	(3,102)	
Interest paid(895)(413)Dividends paid(3,025)(6,210)Net cash from/ [used in] financing activities20,142(17,788)et increase/ [decrease] in cash and cash equivalents4,186(577)sh and cash equivalents at the beginning of the year4,1304,878sh and cash equivalents of the acquired subsidiaries16660ect of foreign exchange rate changes on Cash and cash equivalents(214)(231)sh and cash equivalents at the end of the year8,2684,130inal Information:3,103/202531/03/2024any of Cash and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:31/03/2024ulars8,2684,130sh and cash equivalents8,2684,130ink balance other than cash and cash equivalents21,3006,921rrent Investments21,3006,921ed Deposits more than 12 month's maturity316	Buyback of equity shares [including tax and transaction costs]		(7,250)	
Dividends paid(3,025)(6,210)Net cash from/ [used in] financing activities20,142(17,788)et increase/ [decrease] in cash and cash equivalents4,186(577)sh and cash equivalents at the beginning of the year4,1304,878sh and cash equivalents of the acquired subsidiaries16660ect of foreign exchange rate changes on Cash and cash equivalents(214)(231)sh and cash equivalents at the end of the year8,2684,130and cash equivalents at the end of the year8,2684,130inal Information: ary of Cash and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:31/03/2024ulars31/03/202531/03/2024sh and cash equivalents8,2684,130nk balance other than cash and cash equivalents21,3006,921rrent Investments48,5112,525ed Deposits more than 12 month's maturity316	Lease liabilities [Net]	42	14	
Dividends paid(3,025)(6,210)Net cash from/ [used in] financing activities20,142(17,788)et increase/ [decrease] in cash and cash equivalents4,186(577)sh and cash equivalents at the beginning of the year4,1304,878sh and cash equivalents of the acquired subsidiaries16660ect of foreign exchange rate changes on Cash and cash equivalents(214)(231)sh and cash equivalents at the end of the year8,2684,130and cash equivalents at the end of the year8,2684,130inal Information:31/03/202531/03/2024any of Cash and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:31/03/2024ulars8,2684,130sh and cash equivalents8,2684,130nk balance other than cash and cash equivalents21,3006,921rrent Investments21,3006,92148,511ed Deposits more than 12 month's maturity31616	Interest paid	(895)	(413)	
Net cash from/ [used in] financing activities20,142(17,788)et increase/ [decrease] in cash and cash equivalents4,186(577)sh and cash equivalents at the beginning of the year4,1304,878sh and cash equivalents of the acquired subsidiaries16660ect of foreign exchange rate changes on Cash and cash equivalents(214)(231)sh and cash equivalents at the end of the year8,2684,130and cash equivalents at the end of the year31/03/202531/03/2024annal Information: arry of Cash and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:31/03/2024ulars31/03/202531/03/2024sh and cash equivalents8,2684,130nk balance other than cash and cash equivalents21,3006,921rrent Investments48,5112,525ed Deposits more than 12 month's maturity316	Dividends paid	(3,025)	(6,210)	
At increase/ [decrease] in cash and cash equivalents4,186(577)sh and cash equivalents at the beginning of the year4,1304,878sh and cash equivalents of the acquired subsidiaries16660ect of foreign exchange rate changes on Cash and cash equivalents(214)(231)sh and cash equivalents at the end of the year8,2684,130and linformation:31/03/202531/03/2024any of Cash and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:31/03/2024ulars31/03/202531/03/2024sh and cash equivalents8,2684,130cosh equivalents8,2684,130nk balance other than cash and cash equivalents21,3006,921rrent Investments48,5112,52548,511ed Deposits more than 12 month's maturity316	Net cash from/ [used in] financing activities	17 August and a second s		
sh and cash equivalents at the beginning of the year4,1304,878sh and cash equivalents of the acquired subsidiaries16660ect of foreign exchange rate changes on Cash and cash equivalents(214)(231)sh and cash equivalents at the end of the year8,2684,130anal Information:31/03/202531/03/2024ary of Cash and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:31/03/2025ulars31/03/202531/03/2024sh and cash equivalents8,2684,130nk balance other than cash and cash equivalents21,3006,921rrent Investments48,5112,525ed Deposits more than 12 month's maturity316	et increase/ [decrease] in cash and cash equivalents		and the second sec	
sh and cash equivalents of the acquired subsidiaries 166 60 ect of foreign exchange rate changes on Cash and cash equivalents (214) (231) sh and cash equivalents at the end of the year 8,268 4,130 nal Information: 31/03/2025 31/03/2024 ary of Cash and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months: 31/03/2025 31/03/2024 sh and cash equivalents 8,268 4,130 b and cash equivalents 8,268 4,130 cash and cash equivalents 8,268 4,130 not cash equivalents 3 16 <td>ish and cash equivalents at the beginning of the year</td> <td>and the second se</td> <td></td> <td></td>	ish and cash equivalents at the beginning of the year	and the second se		
ect of foreign exchange rate changes on Cash and cash equivalents(214)(231)sh and cash equivalents at the end of the year8,2684,130anal Information: ary of Cash and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months:31/03/202531/03/2024ulars31/03/202531/03/2024sh and cash equivalents8,2684,130nk balance other than cash and cash equivalents21,3006,921rrent Investments48,5112,525ed Deposits more than 12 month's maturity316	sh and cash equivalents of the acquired subsidiaries	the second se	and the second sec	
sh and cash equivalents at the end of the year 8,268 4,130 nal Information: ary of Cash and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months: 31/03/2025 31/03/2024 ulars 31/03/2025 31/03/2024 4,130 sh and cash equivalents 8,268 4,130 nk balance other than cash and cash equivalents 21,300 6,921 rrent Investments 48,511 2,525 ed Deposits more than 12 month's maturity 3 16	ect of foreign exchange rate changes on Cash and cash equivalents	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
anal Information: ary of Cash and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months: ulars 31/03/2025 sh and cash equivalents 8,268 4,130 nk balance other than cash and cash equivalents 21,300 6,921 rrent Investments 48,511 2,525 ed Deposits more than 12 month's maturity 3				
ary of Cash and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months: 31/03/2025 31/03/2024 ulars 31/03/2024 8,268 4,130 sh and cash equivalents 8,268 4,130 nk balance other than cash and cash equivalents 21,300 6,921 rrent Investments 48,511 2,525 ed Deposits more than 12 month's maturity 3 16	AN EVALUATION DESCRIPTION CONTRACTOR OF SHE ALGORIZ			
ary of Cash and cash equivalents, Bank balance, Current Investments and Fixed Deposits more than 12 months: 31/03/2025 31/03/2024 ulars 31/03/2024 8,268 4,130 sh and cash equivalents 8,268 4,130 nk balance other than cash and cash equivalents 21,300 6,921 rrent Investments 48,511 2,525 ed Deposits more than 12 month's maturity 3 16	onal Information:		1	
ulars 31/03/2025 31/03/2024 sh and cash equivalents 8,268 4,130 nk balance other than cash and cash equivalents 21,300 6,921 rrent Investments 48,511 2,525 ed Deposits more than 12 month's maturity 3 16		nonths:		
sh and cash equivalents8,2684,130nk balance other than cash and cash equivalents21,3006,921rrent Investments48,5112,525ed Deposits more than 12 month's maturity316			31/03/2024	
nk balance other than cash and cash equivalents21,3006,921rrent Investments48,5112,525ed Deposits more than 12 month's maturity316				
rrent Investments48,5112,525ed Deposits more than 12 month's maturity316				
ed Deposits more than 12 month's maturity 3 16			1	
10,002 13,332			the second se	
	LOI .	70,002	15,552	

Ahmedabad, May 20, 2025

MUMBAL)

VINO

Respired accounts

10

For Zydus Litesciences Limited, Dr. thavil P. Patel Managing Director DIN: 00131995